{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+HER2-Negative+Breast+Carcinoma", "query": { "condition": "Recurrent HER2-Negative Breast Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 122, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+HER2-Negative+Breast+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T09:33:23.638Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01697293", "title": "PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Estrogen Receptor Positive", "HER2/Neu Negative", "Recurrent Breast Carcinoma", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Triciribine Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Prescient Therapeutics, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-01", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 2, "location_summary": "Tampa, Florida • The Bronx, New York", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697293" }, { "nct_id": "NCT01158274", "title": "RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "HER2-negative Breast Cancer", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Male Breast Cancer", "Nodal Marginal Zone B-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Rectal Cancer", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Colon Cancer", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Rectal Cancer", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Rectal Cancer", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-07", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01158274" }, { "nct_id": "NCT01288261", "title": "Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "bavituximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2011-01", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-04-21", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01288261" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "ARV-471", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 624, "start_date": "2023-03-03", "completion_date": "2028-05-15", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 87, "location_summary": "Encinitas, California • Fountain Valley, California • Fresno, California + 69 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "San Marcos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05654623" }, { "nct_id": "NCT02774681", "title": "Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Carcinoma Metastatic in the Brain", "Estrogen Receptor Negative", "HER2/Neu Negative", "HER2/Neu Positive", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Cognitive Assessment", "type": "PROCEDURE" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-08-31", "completion_date": "2020-02-16", "has_results": true, "last_update_posted_date": "2020-04-14", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 3, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02774681" }, { "nct_id": "NCT02269670", "title": "Phase II Study of Everolimus Beyond Progression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2014-11-25", "completion_date": "2021-01-25", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269670" }, { "nct_id": "NCT03213041", "title": "Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-09-14", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213041" }, { "nct_id": "NCT01862081", "title": "A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer, Non-small Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2013-07-16", "completion_date": "2017-06-09", "has_results": false, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 10, "location_summary": "Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01862081" }, { "nct_id": "NCT01145430", "title": "Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Male Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2010-06-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-06-25T09:33:23.638Z", "location_count": 6, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01145430" } ] }